Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction - ten commandments
- IDU
- TFT
- Methisazone
- Amantadine
- Ribavirin
- Ara-A
- HIV
- Replicative cycle of HIV
- Suramin
- Zidovudine
- Emtricitabine
- TDF
- Drug interrelations and combination
- Truvada
- Atripla
- Complera
- Quad (stribild)
- GS-7340
- Quad (planned)
- Another planned quad
- Cobicistat & Ritonavir
- HCV
- HCV genome and potential targets
- Available HCV drugs
- Telaprevir
- Boceprevir
- Asunaprevir
- GS-9256
- GS-9451
- Danoprevir
- Vaniprevir
- Narlaprevir
- Simeprevir
- Drugs which target NS5A
- Daclatasvir
- Drugs that target NS5B (nucleoside)
- Sofosbuvir
- Mericitabine
- Drugs that target NS5B (non-nucleoside)
- VX-222
- BI 201335
- Tegobuvir
- Setrobuvir
- Filibuvir
- VCH-916 & VCH-759
- Drugs that target cellular enzymes
- Alisporivir
- The principle for the future treatment of HCV
- Phase II DAA-based combination clinical trials
- HSV
- Acyclovir
- Valaciclovir
- Penciclovir & Famciclovir
- HSV DNA synthesis
- AIC316
- VZV
- BVDU
- Degradation of BVDU to BVU
- Cf 1743 & FV-100
- ASP2151
- HCMV
- Ganciclovir & Valganciclovir
- Phosphonoformic acid: Foscarnet
- HPMPC
- Maribavir
- Letermovir
- Poxviruses
- Post-exposure treatments for monkeypox virus
- HDP-cidofovir
- ST-246
- HBV
- Anti-HBV agents
- Lamivudine
- Adefovir dipivoxil
- Entecavir
- Telbivudine
- Viread
- CHB virologic response
- Influenza virus
- Antiviral influenza replication inhibition
- Zanamivir
- Oseltamivir (tamiflu)
- Tamiflu packaging
- RWJ-270201: Peramivir
- Laninamivir octanoate
- Favipiravir
- Favipiravir mechanism
- Enveloped viruses
- Neplanocin A
- dUY11
- LJ-001
- FGI-106
- Picornaviruses
- Pleconaril
- Pirodavir
- Rupintrivir
- TBZE-029
- City hall
- Rega institute building
- Henri Joseph Rega
- Mentor
- Seed of wisdom
Topics Covered
- Chemotherapy of virus infections, AIDS, and malignant diseases
- Molecular mechanism of action & enzyme targets of antiviral and antitumor agents
- Nucleoside and nucleotide analogues
- Reverse transcriptase inhibitors
- Virus adsorption, fusion and uncoating inhibitors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
De Clercq, E. (2013, September 23). Current trends in antiviral drug development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/LHVX4583.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dr. Erik De Clercq has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.